Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 1/20 | 0.64 |
| ▸ | RORC | P51449 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6577559 | 0.84 | PYGL (0.48) | PYGLRORCMEN1KMT2AALDH1A1 | |
| SCHEMBL23752503 | 0.79 | PYGL (1.00) | PYGLMEN1KMT2AALDH1A1PPARA | |
| SCHEMBL7262405 | 0.79 | PYGL (1.00) | PYGLMEN1KMT2AALDH1A1PPARA | |
| SCHEMBL6575170 | 0.78 | PYGL (0.51) | PYGLTHRATHRBALDH1A1PLAU | |
| SCHEMBL9780857 | 0.74 | KMT2A (0.61) | PYGLKMT2AALDH1A1PPARAL3MBTL1 | |
| SCHEMBL6815435 | 0.74 | SIRT2 (0.54) | RORCMEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL9780778 | 0.72 | KMT2A (0.62) | PYGLMEN1KMT2APPARAL3MBTL1 | |
| SCHEMBL6811372 | 0.72 | GAA (0.52) | RORCMEN1KMT2AALDH1A1GAA | |
| SCHEMBL5110132 | 0.72 | THRA (0.48) | MEN1KMT2ATHRATHRB | |
| SCHEMBL31421852 | 0.71 | MEN1 (0.44) | PYGLRORCMEN1KMT2ATHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1280266-C | Acylphenylurea derivatives, a process for their preparation and their use as pharmaceuticals | AVENTIS PHARMA GMBH (DE) | 2006-10-18 | — | — | CN | disclosed |
| EP-1294682-B1 | ACYLPHENYL UREA DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF AS A MEDICAMENT | AVENTIS PHARMA GMBH (DE) | 2004-04-28 | — | — | EP | disclosed |
| CN-1434796-A | Acylphenylurea derivatives, a process for their preparation and their use as pharmaceuticals | AVENTIS PHARMA GMBH | 2003-08-06 | — | — | CN | disclosed |
| EP-1294682-A1 | ACYLPHENYL UREA DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF AS A MEDICAMENT | Aventis Pharma Deutschland GmbH (DE) | 2003-03-26 | — | — | EP | disclosed |
| US-6506778-B2 | Antidiabetic agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-01-14 | — | — | US | disclosed |
| US-20020151586-A1 | Acylphenylurea derivatives, a process for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2001094300-A1 | ACYLPHENYL UREA DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF AS A MEDICAMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151586-A1 | Acylphenylurea derivatives, a process for their preparation and their use as pharmaceuticals | ACAD11, CYP4F11, CYP4A11 | PYGL 816/4885RORC 3718/4885MEN1 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.